Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiverse Scientific and Economic Studies · Educational Reforms and Innovations · Data Analysis with R
In the manuscript “Characteristics and clinical outcomes of adolescents infected by SARS-CoV-2: a systematic review”, DOI: 10.1590/1984-0462/2024/42/2022241, published in the Rev Paul Pediatr. 2024;42:e2022241, on page 3:
Where it reads:
Table 1.Articles published between January 2020 and April 2022.ReferenceCountryStudy design
- Description of the sample
- Number of participants (n)/age group (years old)
Methodological quality^14^ and level of evidence^12^ Oliveira et al.^27^ BrazilCohortn=6.725/12-1917 points/level 3Clemente et al.^19^ SpainCohortn=77/less than 1816 points/level 3Drouin et al.^20^ CanadaCohortn=36/13-1718 points/level 3Gomes et al.^21^ BrazilCohortn=1320/12-1816 points/level 3Pinto Júnior et al.^22^ BrazilCross-sectionaln=854/10-1917 points/level 4Graff et al.^23^ USACohortn=220/11-1917 points/level 3Macias-Parra et al.^24^ MexicoCross-sectionaln=34/12-1816 points/level 4Oliveira et al.^25^ BrazilCohortn=3589/12-1921 points/level 3Parcha et al.^26^ USACohortn=5573/12-1718 points/level 3Prata-Barbosa et al.^15^ BrazilCohortn=14/12-1716 points/level 3DeBiasi et al.^16^ USACohortn=73/10-1916 points/level 3
It should read:
Table 1.Articles published between January 2020 and April 2022.ReferenceCountryStudy design
- Description of the sample
- Number of participants (n)/age group (years old)
Methodological quality^14^ and level of evidence^12^ Oliveira et al.^27^ BrazilCohortn=6.725/12-1917 points/level 3 ^Afonso et al.17^ BrazilCross-sectionaln=49/10-19 17 points/level 4 ^Alharbi et al.18^ Saudi ArabiaCohortn=9/11-14 16 points/level 3Clemente et al.^19^ SpainCohortn=77/less than 1816 points/level 3Drouin et al.^20^ CanadaCohortn=36/13-1718 points/level 3Gomes et al.^21^ BrazilCohortn=1320/12-1816 points/level 3Pinto Júnior et al.^22^ BrazilCross-sectionaln=854/10-1917 points/level 4Graff et al.^23^ USACohortn=220/11-1917 points/level 3Macias-Parra et al.^24^ MexicoCross-sectionaln=34/12-1816 points/level 4Oliveira et al.^25^ BrazilCohortn=3589/12-1921 points/level 3Parcha et al.^26^ USACohortn=5573/12-1718 points/level 3Prata-Barbosa et al.^15^ BrazilCohortn=14/12-1716 points/level 3DeBiasi et al.^16^ USACohortn=73/10-1916 points/level 3